Hatch‑Waxman, GLP-1s, and the Next Legal Showdown
Shortages and sticker-shock prices for Ozempic, Mounjaro and their siblings ignited a booming trade in cheaper, compounded GLP-1 weight-loss shots. Now that brand-name supply is catching up, a wave of lawsuits and FDA deadlines is testing how far the law should bend for access before it snaps back to protect innovation.